在第三阶段试验中,新药Dapirolizumab Pegol在减少狼疮症状和疲劳方面很有希望。 New drug Dapirolizumab pegol shows promise in reducing lupus symptoms and fatigue, per Phase 3 trials.

一种新药物Dapirolizumab Pegol(DZP)在第三阶段试验期间在减少严重狼疮患者疲劳和疾病活动方面显示出可喜的成果。 A new drug, Dapirolizumab pegol (DZP), showed promising results in reducing fatigue and disease activity in patients with severe lupus during Phase 3 trials. 在欧洲风湿学大会上介绍的这次试验表明,与标准治疗相比,疲劳症和疾病活动措施有了显著改善。 The trial, presented at the European Congress of Rheumatology, indicated significant improvements in fatigue and disease activity measures compared to standard treatments. 然而,DZP尚未获准用于lupus,需要进一步审判以证实这些结果。 However, DZP is not yet approved for use in lupus, and further trials are needed to confirm these results.